 Shyam Raghavan
Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 21 | 2024 | 754 | 7.530 |
Why?
| | Melanoma | 7 | 2024 | 620 | 3.490 |
Why?
| | Biomarkers, Tumor | 10 | 2024 | 1032 | 2.160 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 4 | 2020 | 8 | 1.760 |
Why?
| | Antigens, Neoplasm | 4 | 2024 | 222 | 1.670 |
Why?
| | Nevus, Pigmented | 2 | 2024 | 34 | 1.570 |
Why?
| | Diagnosis, Differential | 12 | 2024 | 1331 | 1.170 |
Why?
| | Tendons | 5 | 2016 | 118 | 1.020 |
Why?
| | Genes, T-Cell Receptor gamma | 2 | 2021 | 3 | 0.970 |
Why?
| | Merkel cell polyomavirus | 1 | 2024 | 3 | 0.940 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2024 | 17 | 0.920 |
Why?
| | Carcinoma, Basal Cell | 2 | 2022 | 66 | 0.920 |
Why?
| | Nevus | 1 | 2024 | 26 | 0.890 |
Why?
| | Melanocytes | 2 | 2022 | 55 | 0.890 |
Why?
| | Cloning, Molecular | 2 | 2021 | 522 | 0.880 |
Why?
| | Xeroderma Pigmentosum | 1 | 2022 | 7 | 0.800 |
Why?
| | Hamartoma | 1 | 2022 | 20 | 0.790 |
Why?
| | Granular Cell Tumor | 1 | 2022 | 7 | 0.790 |
Why?
| | Pityriasis Lichenoides | 1 | 2021 | 1 | 0.780 |
Why?
| | Pathologists | 1 | 2022 | 13 | 0.780 |
Why?
| | Tissue Engineering | 5 | 2016 | 364 | 0.780 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2021 | 18 | 0.770 |
Why?
| | Rhabdoid Tumor | 1 | 2022 | 80 | 0.770 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2020 | 179 | 0.770 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 60 | 0.770 |
Why?
| | Bone Neoplasms | 1 | 2024 | 191 | 0.760 |
Why?
| | Lymphoproliferative Disorders | 1 | 2021 | 46 | 0.750 |
Why?
| | Syphilis | 1 | 2021 | 26 | 0.750 |
Why?
| | Carcinoma | 1 | 2022 | 198 | 0.740 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2020 | 16 | 0.720 |
Why?
| | Lymphoid Enhancer-Binding Factor 1 | 1 | 2020 | 8 | 0.720 |
Why?
| | Immunohistochemistry | 7 | 2024 | 1624 | 0.720 |
Why?
| | Sarcoma, Clear Cell | 1 | 2020 | 8 | 0.710 |
Why?
| | Keratin-7 | 1 | 2020 | 2 | 0.710 |
Why?
| | Eyelid Neoplasms | 1 | 2020 | 7 | 0.710 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2020 | 3 | 0.700 |
Why?
| | Skin Diseases | 1 | 2021 | 121 | 0.690 |
Why?
| | Immunocompromised Host | 1 | 2021 | 192 | 0.680 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2019 | 18 | 0.660 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2019 | 10 | 0.660 |
Why?
| | Skin | 5 | 2024 | 653 | 0.640 |
Why?
| | Humans | 55 | 2024 | 114045 | 0.640 |
Why?
| | Receptors, Androgen | 1 | 2020 | 131 | 0.640 |
Why?
| | Cadherins | 1 | 2020 | 175 | 0.640 |
Why?
| | Ki-1 Antigen | 1 | 2018 | 4 | 0.630 |
Why?
| | Ki-67 Antigen | 1 | 2018 | 102 | 0.610 |
Why?
| | Antigens, CD | 1 | 2020 | 440 | 0.590 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2018 | 40 | 0.580 |
Why?
| | Exanthema | 3 | 2023 | 74 | 0.570 |
Why?
| | Tissue Scaffolds | 4 | 2016 | 179 | 0.550 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 307 | 0.530 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2024 | 191 | 0.520 |
Why?
| | Kidney Transplantation | 1 | 2021 | 538 | 0.510 |
Why?
| | Aged | 14 | 2024 | 18969 | 0.490 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2018 | 445 | 0.480 |
Why?
| | Mastectomy | 1 | 2015 | 99 | 0.470 |
Why?
| | Cell Proliferation | 2 | 2020 | 2173 | 0.450 |
Why?
| | Mammaplasty | 1 | 2015 | 68 | 0.450 |
Why?
| | Female | 27 | 2024 | 59324 | 0.440 |
Why?
| | Skin Abnormalities | 2 | 2023 | 10 | 0.440 |
Why?
| | Aged, 80 and over | 9 | 2024 | 6306 | 0.440 |
Why?
| | Foot | 2 | 2023 | 103 | 0.410 |
Why?
| | Male | 21 | 2024 | 55396 | 0.400 |
Why?
| | Mutation | 5 | 2024 | 3338 | 0.400 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2012 | 33 | 0.390 |
Why?
| | Adipose Tissue | 2 | 2013 | 545 | 0.380 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2012 | 82 | 0.380 |
Why?
| | Appendix | 1 | 2021 | 27 | 0.380 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2021 | 43 | 0.370 |
Why?
| | Stomach Neoplasms | 1 | 2021 | 65 | 0.370 |
Why?
| | Postoperative Complications | 1 | 2021 | 2122 | 0.370 |
Why?
| | Stem Cells | 2 | 2013 | 541 | 0.370 |
Why?
| | DNA Mutational Analysis | 2 | 2024 | 373 | 0.360 |
Why?
| | Drug Eruptions | 2 | 2020 | 26 | 0.360 |
Why?
| | Middle Aged | 15 | 2024 | 26605 | 0.360 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2012 | 286 | 0.330 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2021 | 437 | 0.330 |
Why?
| | Fibroblasts | 1 | 2012 | 834 | 0.280 |
Why?
| | Pancreatic Neoplasms | 2 | 2024 | 721 | 0.280 |
Why?
| | Prognosis | 3 | 2024 | 3315 | 0.260 |
Why?
| | Adult | 13 | 2023 | 30375 | 0.260 |
Why?
| | Soft Tissue Neoplasms | 2 | 2021 | 89 | 0.250 |
Why?
| | Antigens, Viral, Tumor | 1 | 2024 | 6 | 0.240 |
Why?
| | Hematoxylin | 1 | 2024 | 3 | 0.230 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2024 | 7 | 0.230 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 209 | 0.230 |
Why?
| | Extremities | 2 | 2024 | 111 | 0.230 |
Why?
| | Polyomavirus Infections | 1 | 2024 | 22 | 0.230 |
Why?
| | Retrospective Studies | 6 | 2024 | 12521 | 0.220 |
Why?
| | Necrobiosis Lipoidica | 1 | 2023 | 2 | 0.220 |
Why?
| | Livedo Reticularis | 1 | 2023 | 4 | 0.220 |
Why?
| | Leg | 2 | 2023 | 224 | 0.220 |
Why?
| | Tattooing | 1 | 2023 | 11 | 0.220 |
Why?
| | Intestinal Diseases | 1 | 2023 | 33 | 0.210 |
Why?
| | Esophagogastric Junction | 1 | 2022 | 42 | 0.210 |
Why?
| | Insulins | 1 | 2023 | 32 | 0.200 |
Why?
| | Comparative Genomic Hybridization | 1 | 2022 | 28 | 0.200 |
Why?
| | Uveitis, Anterior | 1 | 2021 | 11 | 0.190 |
Why?
| | S100 Proteins | 1 | 2022 | 37 | 0.190 |
Why?
| | Lymphoma, T-Cell | 1 | 2021 | 21 | 0.190 |
Why?
| | DNA Helicases | 1 | 2022 | 133 | 0.190 |
Why?
| | Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2021 | 1 | 0.190 |
Why?
| | Mesenchymoma | 1 | 2021 | 7 | 0.190 |
Why?
| | Adolescent | 6 | 2022 | 17800 | 0.190 |
Why?
| | Pemphigus | 1 | 2021 | 8 | 0.190 |
Why?
| | Child | 6 | 2024 | 18401 | 0.190 |
Why?
| | Erythema | 1 | 2021 | 25 | 0.180 |
Why?
| | Liposarcoma, Myxoid | 1 | 2021 | 6 | 0.180 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2021 | 17 | 0.180 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 28 | 0.180 |
Why?
| | Nevus, Blue | 1 | 2020 | 1 | 0.180 |
Why?
| | Phospholipids | 1 | 2022 | 194 | 0.180 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 87 | 0.180 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 2020 | 2 | 0.180 |
Why?
| | Scrotum | 1 | 2020 | 23 | 0.180 |
Why?
| | Histiocytes | 1 | 2020 | 6 | 0.180 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2020 | 35 | 0.180 |
Why?
| | Child, Preschool | 4 | 2021 | 9114 | 0.180 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2020 | 53 | 0.170 |
Why?
| | Smooth Muscle Tumor | 1 | 2020 | 6 | 0.170 |
Why?
| | Celiac Disease | 1 | 2023 | 264 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1117 | 0.170 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2020 | 182 | 0.170 |
Why?
| | Hodgkin Disease | 1 | 2021 | 121 | 0.170 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2019 | 14 | 0.160 |
Why?
| | Paired Box Transcription Factors | 1 | 2019 | 37 | 0.160 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2020 | 59 | 0.160 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2020 | 138 | 0.160 |
Why?
| | Intestinal Perforation | 1 | 2019 | 39 | 0.160 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2019 | 4 | 0.160 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 295 | 0.160 |
Why?
| | Myositis, Inclusion Body | 1 | 2019 | 11 | 0.160 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 244 | 0.160 |
Why?
| | Surgical Flaps | 1 | 2020 | 121 | 0.160 |
Why?
| | Sjogren's Syndrome | 1 | 2019 | 41 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 152 | 0.160 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 228 | 0.160 |
Why?
| | beta Catenin | 1 | 2020 | 218 | 0.160 |
Why?
| | Nuclear Proteins | 1 | 2022 | 591 | 0.150 |
Why?
| | Tumor Suppressor Proteins | 1 | 2020 | 283 | 0.150 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2020 | 196 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 381 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 850 | 0.140 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 393 | 0.140 |
Why?
| | Proto-Oncogene Proteins | 1 | 2020 | 607 | 0.140 |
Why?
| | Biopsy | 1 | 2020 | 1024 | 0.140 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 577 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2020 | 694 | 0.130 |
Why?
| | Hospitals, County | 1 | 2016 | 10 | 0.130 |
Why?
| | Pericardium | 1 | 2016 | 50 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 660 | 0.130 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1690 | 0.130 |
Why?
| | Lacerations | 1 | 2016 | 27 | 0.130 |
Why?
| | Wrist Injuries | 1 | 2016 | 25 | 0.130 |
Why?
| | Peripheral Nerve Injuries | 1 | 2016 | 32 | 0.130 |
Why?
| | RNA | 1 | 2022 | 806 | 0.130 |
Why?
| | Lower Extremity | 3 | 2023 | 334 | 0.130 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 31 | 0.120 |
Why?
| | Transcription Factors | 1 | 2022 | 1526 | 0.120 |
Why?
| | Microvessels | 1 | 2015 | 66 | 0.120 |
Why?
| | Breast | 1 | 2015 | 138 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1257 | 0.120 |
Why?
| | Transcriptome | 1 | 2019 | 723 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1735 | 0.110 |
Why?
| | Inflammation | 1 | 2023 | 2464 | 0.100 |
Why?
| | Cohort Studies | 2 | 2020 | 4883 | 0.100 |
Why?
| | Patient Compliance | 1 | 2016 | 524 | 0.100 |
Why?
| | Polymers | 2 | 2023 | 448 | 0.100 |
Why?
| | Collagen | 1 | 2013 | 414 | 0.090 |
Why?
| | Drug Synergism | 1 | 2012 | 315 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 315 | 0.090 |
Why?
| | Bioreactors | 1 | 2011 | 43 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 428 | 0.090 |
Why?
| | Prospective Studies | 3 | 2023 | 6195 | 0.090 |
Why?
| | Rats, Wistar | 1 | 2011 | 368 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2020 | 9049 | 0.090 |
Why?
| | Rabbits | 1 | 2011 | 733 | 0.090 |
Why?
| | Extracellular Matrix | 2 | 2024 | 436 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 1875 | 0.090 |
Why?
| | Young Adult | 4 | 2020 | 10444 | 0.080 |
Why?
| | Vascular Surgical Procedures | 2 | 2009 | 260 | 0.080 |
Why?
| | Colon | 1 | 2021 | 232 | 0.080 |
Why?
| | Esophagus | 1 | 2021 | 224 | 0.080 |
Why?
| | Vascular Neoplasms | 1 | 2009 | 15 | 0.080 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2009 | 22 | 0.080 |
Why?
| | Angioplasty | 1 | 2009 | 40 | 0.080 |
Why?
| | Vaccines, DNA | 1 | 2008 | 29 | 0.080 |
Why?
| | Polyethyleneimine | 1 | 2008 | 18 | 0.080 |
Why?
| | Cells, Cultured | 2 | 2013 | 3861 | 0.070 |
Why?
| | Sarcoma | 1 | 2009 | 137 | 0.070 |
Why?
| | Microspheres | 1 | 2008 | 123 | 0.070 |
Why?
| | Education, Medical, Undergraduate | 1 | 2009 | 160 | 0.070 |
Why?
| | Animals | 6 | 2023 | 31565 | 0.070 |
Why?
| | Computer Simulation | 1 | 2009 | 873 | 0.060 |
Why?
| | Milk Proteins | 1 | 2023 | 36 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2023 | 84 | 0.050 |
Why?
| | Clinical Competence | 1 | 2009 | 882 | 0.050 |
Why?
| | Duodenum | 1 | 2023 | 62 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 42 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 2958 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2022 | 72 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2021 | 29 | 0.050 |
Why?
| | Hyperplasia | 1 | 2022 | 163 | 0.050 |
Why?
| | In Situ Hybridization | 1 | 2022 | 292 | 0.050 |
Why?
| | Hepatocytes | 1 | 2022 | 195 | 0.050 |
Why?
| | Genes, T-Cell Receptor | 1 | 2020 | 6 | 0.050 |
Why?
| | CD4-CD8 Ratio | 1 | 2020 | 19 | 0.050 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 92 | 0.050 |
Why?
| | Lip | 1 | 2020 | 20 | 0.050 |
Why?
| | Cattle | 1 | 2023 | 918 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2022 | 256 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 64 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2021 | 274 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 126 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2021 | 308 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 396 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 452 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 275 | 0.040 |
Why?
| | Allergens | 1 | 2023 | 410 | 0.040 |
Why?
| | Machine Learning | 1 | 2023 | 315 | 0.040 |
Why?
| | Ileostomy | 1 | 2019 | 18 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2023 | 766 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 917 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 544 | 0.040 |
Why?
| | Mice | 3 | 2023 | 14843 | 0.040 |
Why?
| | Colectomy | 1 | 2019 | 86 | 0.040 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 220 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2023 | 532 | 0.040 |
Why?
| | Synoviocytes | 1 | 2016 | 10 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 925 | 0.030 |
Why?
| | Hydrogels | 1 | 2023 | 573 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1791 | 0.030 |
Why?
| | San Francisco | 1 | 2016 | 54 | 0.030 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2016 | 192 | 0.030 |
Why?
| | Psychology | 1 | 2016 | 82 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 314 | 0.030 |
Why?
| | Prevalence | 1 | 2021 | 2247 | 0.030 |
Why?
| | Rats | 1 | 2023 | 4913 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1633 | 0.030 |
Why?
| | Aftercare | 1 | 2016 | 186 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 924 | 0.030 |
Why?
| | Swine | 1 | 2016 | 687 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1014 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 198 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 4680 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2371 | 0.030 |
Why?
| | Social Support | 1 | 2016 | 528 | 0.030 |
Why?
| | Recovery of Function | 1 | 2016 | 573 | 0.030 |
Why?
| | Mental Health Services | 1 | 2016 | 316 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2016 | 1080 | 0.020 |
Why?
| | Tensile Strength | 1 | 2011 | 88 | 0.020 |
Why?
| | Elastic Modulus | 1 | 2011 | 116 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2009 | 77 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2009 | 160 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2011 | 669 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3039 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 178 | 0.020 |
Why?
| | Educational Measurement | 1 | 2009 | 235 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 4392 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2009 | 405 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 304 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1696 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3397 | 0.020 |
Why?
| | Students, Medical | 1 | 2009 | 262 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 295 | 0.020 |
Why?
| | Kinetics | 1 | 2008 | 1547 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2008 | 1075 | 0.010 |
Why?
| | Curriculum | 1 | 2009 | 813 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2629 | 0.010 |
Why?
|
|
Raghavan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|